{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003972","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.602911+00:00","generated_at":"2026-06-07T02:16:02.809942+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prothena reports $621M cash at year-end 2023; pipeline updates on PRX012, PRX123, birtamimab","bullets":["Cash, cash equivalents, and restricted cash ~$621M as of Dec 31, 2023; sufficient capital beyond ongoing trials.","PRX012 (Alzheimer's): Phase 1 data supports once-monthly dosing; dose escalation to 200-400mg underway.","PRX123 (Alzheimer's vaccine): IND cleared and Fast Track designation; Phase 1 timeline update expected in 2024.","Birtamimab (AL amyloidosis): Phase 3 AFFIRM-AL enrollment on track; topline results expected 4Q24-2Q25.","Partnered programs with BMS, Roche, Novo Nordisk remain on track; BMS-986446 moving to Phase 2 in 1H24."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003972","json":"https://secwatch.observer/filing/0001193125-24-003972.json","markdown":"https://secwatch.observer/filing/0001193125-24-003972.md","text":"https://secwatch.observer/filing/0001193125-24-003972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000119312524003972/0001193125-24-003972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000119312524003972/d707357d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:16:02.809942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}